Glyoxalase I Glu111Ala Polymorphism in Patients with Breast Cancer

Germanová, Anna; Tesařová, Petra; Jáchymová, M; Zvára, Karel; Zima, Tomáš; Kalousová, Marta

doi:10.1080/07357900802350822

Cited by 15 publications

(23 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In contrast to our observation, Antognelli and co‐investigators demonstrated that women with Ala/Glu and Glu/Glu genotypes or carriers of Glu allele were associated with breast cancer risk suggesting a possible role of Glu allele in progression of local to advanced breast cancer 15 . Some investigators have determined the genotype and allelic frequencies of GLOI Ala111Glu polymorphism but did not examine the correlation with breast cancer risk 14 . The odds ratio noted for Ala/Glu and Glu/Glu genotypes or carriers of Glu allele in the present study were much lower than the values reported by Antognelli and co‐investigators 15 .…”

Section: Discussioncontrasting

confidence: 99%

“…However, the frequencies of the genotypes and alleles were increased in breast cancers than in the controls irrespective of ethnicity. Several studies reported that Glu allele frequency in different normal populations across the world showed values between 27.2% and 51.7% 14,15,18,27–31 . Our result on Glu allele frequency in the Malay, Chinese and Indian control groups is also within the reported range.…”

Section: Discussionsupporting

confidence: 85%

“…Our result on Glu allele frequency in the Malay, Chinese and Indian control groups is also within the reported range. Antognelli and co‐investigators 15 showed that the distribution of genotype and allele frequencies was significantly different between Italian breast cancer patients and normal individuals but similar observation was not noted among Czech women 14 . The Ala111Glu genotype and allele frequencies in the Malay breast cancer patients were not significantly different from the Italian (21.8% for Ala/Ala, 47.7% for Ala/Glu, 30.5% for Glu/Glu; P = 0.597 and 54.4% for Glu, 45.6% for Ala; P = 0.394) 15 and Czech (24.8% for Ala/Ala, 40.7% for Ala/Glu34.5% for Glu/Glu; P = 0.575 and 54.9% for Glu allele, 45.1% for Ala; P = 0.465) patients 14 .…”

Section: Discussionmentioning

confidence: 92%

See 2 more Smart Citations

Glyoxalase I Ala111Glu gene polymorphism: No association with breast cancer risk but correlated with absence of progesterone receptor

Naidu

Har

Taib

2010

Pathology International

View full text Add to dashboard Cite

The aim of the present study was to evaluate the association between the Glyoxalase I (GLOI) Ala111Glu polymorphism and breast cancer risk among the major Malaysian ethnic groups, the Malays, Chinese and Indians, as well as clinico-pathological characteristics of these patients. Genotyping of GLOI gene was performed on blood samples obtained from 387 patients and 252 normal healthy women who had no history of any malignancy using the polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) method. The genotype and allele frequencies of GLOI polymorphism were not significantly different between the patients and normal individuals among the Malays (P= 0.721, 0.402), Chinese (P= 0.208, 0.079) and Indians (P= 0.612, 0.349), respectively. The Malay, Chinese and Indian women who were Glu/Glu homozygotes (P= 0.419, 0.093, 0.367), Ala/Glu heterozygotes (P= 0.648, 0.182, 0.402) and carriers of Glu allele (P= 0.402, 0.079, 0.349), respectively, were not associated with breast cancer risk. The Glu allele genotype was significantly associated with absence of progesterone receptor (P= 0.036). Thus, the polymorphic variant of the GLOI gene might not be a useful genetic marker to identify Malaysian Malay, Chinese or Indian women who could be at greater risk of developing breast cancer.

show abstract

Section: Discussioncontrasting

confidence: 99%

Section: Discussionsupporting

confidence: 85%

Section: Discussionmentioning

confidence: 92%

See 1 more Smart Citation

Glyoxalase I Ala111Glu gene polymorphism: No association with breast cancer risk but correlated with absence of progesterone receptor

Naidu

Har

Taib

2010

Pathology International

View full text Add to dashboard Cite

show abstract

“…Nevertheless, other groups have demonstrated that AGEs accumulate in mamma carcinoma [53] and that glyoxalase expression [54] and polymorphisms are relevant for breast cancer [55]. Consequently, targeting glyoxalase has been proposed as cancer therapy [10], [56] and even oral consumption of methylglyoxal has been investigated in mice to treat cancer [57].…”

Section: Discussionmentioning

confidence: 99%

Differential Response to α-Oxoaldehydes in Tamoxifen Resistant MCF-7 Breast Cancer Cells

et al. 2014

View full text Add to dashboard Cite

Tamoxifen is the standard adjuvant endocrine therapy for estrogen-receptor positive premenopausal breast cancer patients. However, tamoxifen resistance is frequently observed under therapy. A tamoxifen resistant cell line has been generated from the estrogen receptor positive mamma carcinoma cell line MCF-7 and was analyzed for putative differences in the aldehyde defence system and accumulation of advanced glycation end products (AGE). In comparison to wt MCF-7 cells, these tamoxifen resistant cells were more sensitive to the dicarbonyl compounds glyoxal and methylglyoxal and displayed increased caspase activity, p38-MAPK- and IκBα-phosphorylation. However, mRNA accumulation of the aldehyde- and AGE-defence enzymes glyoxalase-1 and -2 (GLO1, GLO2) as well as fructosamine-3-kinase (FN3K) was not significantly altered. Tamoxifen resistant cells contained less free sulfhydryl-groups (glutathione) suggesting that the increased sensitivity towards the dicarbonyls was due to a higher sensitivity towards reactive oxygen species which are associated with dicarbonyl stress. To further analyse, if these data are of more general importance, key experiments were replicated with tamoxifen resistant MCF-7 cell lines from two independent sources. These cell lines were also more sensitive to aldehydes, especially glyoxal, but were different in their cellular signalling responses to the aldehydes. In conclusion, glyoxalases and other aldehyde defence enzymes might represent a promising target for the therapy of tamoxifen resistant breast cancers.

show abstract

“…We studied the Glu111Ala polymorphism of glyoxalase I in patients with breast cancer 36 and were able to show that the higher frequency of the mutated C allele was found in patients with negative estrogen receptors and in patients and more advanced disease (clinical stage III) compared to controls (P < 0.05) suggesting that the presence of the C allele could be a negative prognostic factor in breast cancer. In a large Italian study of patients with breast cancer cancer 37 polymorphism of glyoxalase I was associated with breast cancer in univariate analysis but a number of confounding factors obfuscate the results.…”

Section: Ages Their Metabolism and Cancermentioning

confidence: 99%

HMGB1, S100 proteins and other RAGE ligands in cancer - markers, mediators and putative therapeutic targets

et al. 2016

View full text Add to dashboard Cite

Background and Aims. Activation of RAGE due to its increased expression in cancer cells or its stimulation by multiple ligands (AGEs, HMGB1, S100 proteins, etc.) may contribute to the proliferation, invasiveness of tumor cells and formation of distant metastases and also to the resistance of cancer to treatment. RAGE ligands could thus become both useful markers of disease severity and its outcome and, a potential therapeutic target. Conclusions. Better understanding of the role of RAGE activation in different types of cancer may help to define the role of ligand/RAGE antagonists as promising cancer treatment.

show abstract

Glyoxalase I Glu111Ala Polymorphism in Patients with Breast Cancer

Cited by 15 publications

References 31 publications

Glyoxalase I Ala111Glu gene polymorphism: No association with breast cancer risk but correlated with absence of progesterone receptor

Glyoxalase I Ala111Glu gene polymorphism: No association with breast cancer risk but correlated with absence of progesterone receptor

Differential Response to α-Oxoaldehydes in Tamoxifen Resistant MCF-7 Breast Cancer Cells

HMGB1, S100 proteins and other RAGE ligands in cancer - markers, mediators and putative therapeutic targets

Contact Info

Product

Resources

About